Alzamend Neuro, Inc.ALZNNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank22
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P22
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-12.97%
2024-53.09%
20234.31%
202295.50%
20218.52%
2020156.30%
2019127.64%
2018-54.83%
20171732.82%
20160.00%